摘要
目的:探讨波生坦治疗特发性肺动脉高压(IPAH)的疗效与安全性。方法:16例IPAH患者予波生坦口服治疗20周,比较治疗前后患者心功能、6分钟步行距离(6MWD)、肺动脉压力以及血常规、肝肾功能变化。结果:患者心功能由治疗前Ⅲ级13例、Ⅳ级3例变为Ⅱ级14例、Ⅲ级2例。6MWD较治疗前明显延长(P<0.01),肺动脉收缩压、肺动脉平均压及肺动脉舒张压均较治疗前显著降低(P<0.01),患者血常规、肝肾功能较治疗前无明显变化。结论:口服波生坦治疗IPAH可明显改善患者的临床症状与血流动力学指标,安全性好。
Objective： To investigate the efficacy and safety on the treatment of bosentan in idiopathic pulmonary arterial hypertension（IPAH）.Methods： 16 patients with IPAH were treated with oral bosentan for 20 weeks.Cardiac function,6-minute walk distance（6MWD）,pulmonary artery pressure,liver and kidney function changes were compared before and after the treatment.Results： After treatment,13 cases with grade Ⅲ and 3 cases with grade Ⅳ of cardiac function turned into 14 cases with grade Ⅱ and 2 cases with grade Ⅲ.6MWD was significantly longer than that before treatment（P〈0.01）.Pulmonary artery systolic pressure,mean pulmonary artery pres-sure and pulmonary artery diastolic pressure was significantly lower than before treatment（P〈0.01）.There were no significant changes in liver and kidney function of the patients before and after treatment.Conclusions： Oral bosentan therapy in patients with IPAH can signifi-cantly improve the clinical symptoms and hemodynamics,which has good security.
出处
《现代生物医学进展》
CAS
2012年第11期2104-2106,共3页
Progress in Modern Biomedicine
关键词
波生坦
特发性肺动脉高压
疗效
安全性
Bosentan
Idiopathic pulmonary hypertension
Efficacy
Security
